Sirolimus and progeria: comparing CREST results with published research

Deciding which candidates to investigate first

Hutchinson–Gilford progeria syndrome (HGPS) is a rare genetic disease. Recruiting patients for clinical trials is difficult, and there is limited capacity to study several treatments at once. Choosing which candidates merit further investigation is therefore an important part of development.

Drug repurposing looks for new uses for medicines that have already been developed. Existing research can inform a new program, but prior approval does not establish safety or efficacy in another disease. Computational screening helps prioritize candidates; experiments and clinical studies must determine whether they work.

Where sirolimus ranked in CREST

CREST compares gene-expression patterns associated with disease and drug exposure. It looks for compounds whose effects run in the opposite direction to the disease signature. That reversal provides a reason to investigate a candidate, rather than a direct measure of therapeutic benefit.

These values describe one analysis under a particular set of data and assumptions. A high rank does not establish efficacy in patients. Relevant questions include whether the result persists across cell types, experimental conditions, and concentrations, and whether it helps prioritize candidates for follow-up.

How the result relates to earlier research

Sirolimus, also called rapamycin, inhibits mTOR. In HGPS, an abnormal protein called progerin accumulates and disrupts nuclear structure and cellular function. Evidence that rapamycin promotes autophagy and progerin clearance provides a biological rationale for studying this drug.

A 2011 review by Mendelsohn and Larrick and a 2012 paper by Graziotto and colleagues describe this line of research. Observations in HGPS fibroblasts connect mTOR inhibition with changes in disease-associated cellular features. They provide context for interpreting the computational ranking.

In a 2018 PNAS study, DuBose and colleagues investigated the related mTOR inhibitor everolimus in fibroblasts from patients with several laminopathies. The study reported improvements in nuclear morphology, senescence, and proliferation. Those results should not be treated as interchangeable with evidence for sirolimus, or as proof of clinical benefit.

A blood-vessel model is not a clinical trial

Abutaleb and colleagues’ 2023 study tested lonafarnib and everolimus in tissue-engineered blood vessels made from HGPS patient-derived iPSCs. The combination improved some vascular and cellular measures. These were laboratory results, distinct from the clinical trial discussed in the paper.

The findings support further study of the combination. Its clinical efficacy, dosing, and tolerability must be assessed using evidence from patients.

What this comparison establishes

The relationship between sirolimus and HGPS was studied well before CREST. This example compares a highly ranked candidate from an internal screen with existing biological research. It is not a claim that CREST discovered sirolimus as a treatment.

Agreement with the literature is useful when assessing an analysis, but it cannot establish performance in new diseases or replace external validation. That requires documented datasets, comparators, analysis timing, and reproducible evaluation on independent data.

Our aim is to help researchers decide what to investigate next. A ranking is most useful when it is accompanied by the relevant mechanisms, the type of supporting evidence, and the questions that remain unresolved.